Immune Tolerance News Today

Two Global Phase 2 Clinical Trials, the Phase 2 portion of ACeD-it and Phase 2a SynCeD Studies, are Ongoing in Individuals with Celiac Disease New Data Presented During Digestive Disease Week® 2024

Checking for and categorizing a suspected allergy allow physicians to draw up a management plan.

/PRNewswire/ -- The Lupus Foundation of America (LFA) is pleased to recognize two leading lupus researchers at the 2023 Evelyn V. Hess Reception. This year,...

CAMBRIDGE, Mass. & LAUSANNE, Switzerland, October 19, 2023--Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced today that Deborah Geraghty, Ph.D., president and chief executive officer, will participate in the BofA Healthcare Trailblazers Private Company Conference on Thursday, October 26, 2023, in Boston, Mass.

Phase 2 data on the investigational drug frexalimab show favorable safety and significant reduction in new T1 brain lesions in relapsing MS.

Two phase 3 trials of the once-monthly SEL-212 in refractory gout achieved and maintained serum uric acid

Investigational treatment found to be highly effective in blocking gluten-specific T cells in celiac disease.

Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort... | June 15, 2023

Researchers reviewed the impact of endometrial microbiota on immune tolerance during pregnancy.

An experimental approach to enhancing a standard cat allergy treatment made it more effective and faster acting, and the benefits persisted for a year after treatment ended, a study supported by the National Institutes of Health has found. The findings were published in the Journal of Allergy and Clinical Immunology. Allergen immunotherapy, often called allergyAn experimental approach to enhancing a standard cat allergy treatment made it more effective and faster acting, and the benefits persist...